227 related articles for article (PubMed ID: 23518928)
1. TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression.
Liu M; Ingle JN; Fridley BL; Buzdar AU; Robson ME; Kubo M; Wang L; Batzler A; Jenkins GD; Pietrzak TL; Carlson EE; Goetz MP; Northfelt DW; Perez EA; Williard CV; Schaid DJ; Nakamura Y; Weinshilboum RM
Mol Endocrinol; 2013 Apr; 27(4):657-70. PubMed ID: 23518928
[TBL] [Abstract][Full Text] [Related]
2. Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.
Ho MF; Bongartz T; Liu M; Kalari KR; Goss PE; Shepherd LE; Goetz MP; Kubo M; Ingle JN; Wang L; Weinshilboum RM
Mol Endocrinol; 2016 Mar; 30(3):382-98. PubMed ID: 26866883
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression.
Liu M; Wang L; Bongartz T; Hawse JR; Markovic SN; Schaid DJ; Mushiroda T; Kubo M; Nakamura Y; Kamatani N; Goss PE; Ingle JN; Weinshilboum RM
Breast Cancer Res; 2012 Mar; 14(2):R41. PubMed ID: 22405131
[TBL] [Abstract][Full Text] [Related]
4. SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.
Dudenkov TM; Ingle JN; Buzdar AU; Robson ME; Kubo M; Ibrahim-Zada I; Batzler A; Jenkins GD; Pietrzak TL; Carlson EE; Barman P; Goetz MP; Northfelt DW; Moreno-Aspita A; Williard CV; Kalari KR; Nakamura Y; Wang L; Weinshilboum RM
Breast Cancer Res Treat; 2017 Jul; 164(1):189-199. PubMed ID: 28429243
[TBL] [Abstract][Full Text] [Related]
5. Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer.
Friesenhengst A; Pribitzer-Winner T; Miedl H; Pröstling K; Schreiber M
Horm Cancer; 2018 Apr; 9(2):128-138. PubMed ID: 29363090
[TBL] [Abstract][Full Text] [Related]
6. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Kinoshita Y; Chen S
Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
[TBL] [Abstract][Full Text] [Related]
7. Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D
Lundqvist J; Kirkegaard T; Laenkholm AV; Duun-Henriksen AK; Bak M; Feldman D; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2018 Mar; 177():171-178. PubMed ID: 28610873
[TBL] [Abstract][Full Text] [Related]
8. Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.
Liu M; Goss PE; Ingle JN; Kubo M; Furukawa Y; Batzler A; Jenkins GD; Carlson EE; Nakamura Y; Schaid DJ; Chapman JA; Shepherd LE; Ellis MJ; Khosla S; Wang L; Weinshilboum RM
Mol Endocrinol; 2014 Oct; 28(10):1740-51. PubMed ID: 25148458
[TBL] [Abstract][Full Text] [Related]
9. Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts.
Knower KC; To SQ; Takagi K; Miki Y; Sasano H; Simpson ER; Clyne CD
Breast Cancer Res Treat; 2012 Apr; 132(2):765-71. PubMed ID: 22237979
[TBL] [Abstract][Full Text] [Related]
10. Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women.
Straume AH; Knappskog S; Lønning PE
J Steroid Biochem Mol Biol; 2012 Jan; 128(1-2):69-75. PubMed ID: 21939764
[TBL] [Abstract][Full Text] [Related]
11. SIRT1 positively regulates breast cancer associated human aromatase (CYP19A1) expression.
Holloway KR; Barbieri A; Malyarchuk S; Saxena M; Nedeljkovic-Kurepa A; Cameron Mehl M; Wang A; Gu X; Pruitt K
Mol Endocrinol; 2013 Mar; 27(3):480-90. PubMed ID: 23340254
[TBL] [Abstract][Full Text] [Related]
12. Aromatase promoter I.f is regulated by estrogen receptor alpha (ESR1) in mouse hypothalamic neuronal cell lines.
Yilmaz MB; Wolfe A; Cheng YH; Glidewell-Kenney C; Jameson JL; Bulun SE
Biol Reprod; 2009 Nov; 81(5):956-65. PubMed ID: 19605792
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Ingle JN; Schaid DJ; Goss PE; Liu M; Mushiroda T; Chapman JA; Kubo M; Jenkins GD; Batzler A; Shepherd L; Pater J; Wang L; Ellis MJ; Stearns V; Rohrer DC; Goetz MP; Pritchard KI; Flockhart DA; Nakamura Y; Weinshilboum RM
J Clin Oncol; 2010 Nov; 28(31):4674-82. PubMed ID: 20876420
[TBL] [Abstract][Full Text] [Related]
14. CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer.
Thompson DJ; O'Mara TA; Glubb DM; Painter JN; Cheng T; Folkerd E; Doody D; Dennis J; Webb PM; ; Gorman M; Martin L; Hodgson S; ; Michailidou K; Tyrer JP; Maranian MJ; Hall P; Czene K; Darabi H; Li J; Fasching PA; Hein A; Beckmann MW; Ekici AB; Dörk T; Hillemanns P; Dürst M; Runnebaum I; Zhao H; Depreeuw J; Schrauwen S; Amant F; Goode EL; Fridley BL; Dowdy SC; Winham SJ; Salvesen HB; Trovik J; Njolstad TS; Werner HM; Ashton K; Proietto T; Otton G; Carvajal-Carmona L; Tham E; Liu T; Mints M; ; Scott RJ; McEvoy M; Attia J; Holliday EG; Montgomery GW; Martin NG; Nyholt DR; Henders AK; Hopper JL; Traficante N; ; Ruebner M; Swerdlow AJ; Burwinkel B; Brenner H; Meindl A; Brauch H; Lindblom A; Lambrechts D; Chang-Claude J; Couch FJ; Giles GG; Kristensen VN; Cox A; Bolla MK; Wang Q; Bojesen SE; Shah M; Luben R; Khaw KT; Pharoah PD; Dunning AM; Tomlinson I; Dowsett M; Easton DF; Spurdle AB
Endocr Relat Cancer; 2016 Feb; 23(2):77-91. PubMed ID: 26574572
[TBL] [Abstract][Full Text] [Related]
15. Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
Lunardi G; Piccioli P; Bruzzi P; Notaro R; Lastraioli S; Serra M; Marroni P; Bighin C; Mansutti M; Puglisi F; Porpiglia M; Ponzone R; Bisagni G; Garrone O; Cavazzini G; Clavarezza M; Del Mastro L
Breast Cancer Res Treat; 2013 Jan; 137(1):167-74. PubMed ID: 23129173
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms associated with circulating sex hormone levels in postmenopausal women.
Dunning AM; Dowsett M; Healey CS; Tee L; Luben RN; Folkerd E; Novik KL; Kelemen L; Ogata S; Pharoah PD; Easton DF; Day NE; Ponder BA
J Natl Cancer Inst; 2004 Jun; 96(12):936-45. PubMed ID: 15199113
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
Napoli N; Rastelli A; Ma C; Colleluori G; Vattikuti S; Armamento-Villareal R
Pharmacogenet Genomics; 2015 Aug; 25(8):377-81. PubMed ID: 26049585
[TBL] [Abstract][Full Text] [Related]
18. Regulation of aromatase expression in breast cancer tissue.
Bulun SE; Lin Z; Zhao H; Lu M; Amin S; Reierstad S; Chen D
Ann N Y Acad Sci; 2009 Feb; 1155():121-31. PubMed ID: 19250199
[TBL] [Abstract][Full Text] [Related]
19. Regulation of aromatase induction by nuclear receptor coregulator PELP1.
Vadlamudi RK; Rajhans R; Chakravarty D; Nair BC; Nair SS; Evans DB; Chen S; Tekmal RR
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):211-8. PubMed ID: 19800002
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
Napoli N; Rastelli A; Ma C; Yarramaneni J; Vattikutti S; Moskowitz G; Giri T; Mueller C; Kulkarny V; Qualls C; Ellis M; Armamento-Villareal R
Bone; 2013 Aug; 55(2):309-14. PubMed ID: 23643682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
